Background
==========

The link between inflammation and tumour development has been widely reported and recently, in an update to their seminal paper on the hallmarks of cancer, Hanahan and Weinberg refer to inflammation as an "enabling characteristic" for tumour development \[[@B1]\]. This link is well illustrated in gynaecological malignancies. The processes of ovulation and menstruation are associated with inflammation of the ovarian surface and endometrial epithelia \[[@B2],[@B3]\]. During ovulation there is an increase in the macrophage population in the perifollicular stroma of pre-ovulatory follicles \[[@B4],[@B5]\]. These macrophages produce pro-inflammatory cytokines Interleukin (IL)-6, IL-1β and Tumour Necrosis Factor (TNF), \[[@B2]\]. Oestrogen in the endometrium also induces the up-regulation of these pro-inflammatory cytokines \[[@B6]\]. Over time, the cyclical process of epithelial damage and repair, involving inflammation, predisposes to neoplastic growth. Not only does inflammation play a role in tumourigenesis, it also facilitates disease progression. The tumour microenvironment is rich in inflammatory mediators produced by tumour cells and infiltrating leukocytes \[[@B7]-[@B9]\]. Specifically, IL-6 triggers tumour cells to produce matrix metalloproteinase (MMP)-9 that promotes tumour growth by initiating angiogenesis \[[@B10]\].

C reactive protein (CRP), an acute phase protein produced by hepatocytes is the most widely used indicator of inflammation. The transcription of CRP is induced by IL-6 alone while the presence of either IL-1β or TNF augments its production \[[@B11],[@B12]\]. Gynaecological cancer patients exhibit elevated levels of CRP, however these levels are not static. In a preliminary study of melanoma and ovarian cancer patients, serum CRP levels oscillated about a mean with a periodicity (λ) of 7 days \[[@B13]\]. The dynamic state of inflammation could indicate an underlying persistent but regulated anti-tumour immune response in the cancer patients, which is characterised by a cyclical repeating process of endogenous auto-vaccination, preceding suppression by regulatory cells.

In the past few decades the role of the adaptive immune system in driving anti-tumour immunity has been highlighted. Studies have shown a positive correlation between the number of tumour infiltrating effector T cells and patient survival, as well as a negative correlation with Foxp3^+^CD25^Hi^CD4^+^ regulatory T cells \[[@B14],[@B15]\]. Inflammatory cytokines and chemokines such as TNF and CCL22 facilitate the infiltration of T cells into the tumour microenvironment. When activated, effector T cells up-regulate CD25 and transiently express FoxP3 \[[@B16]\]. This enables them to expand and secrete pro-inflammatory cytokines. FoxP3^+^CD25^Hi^CD4^+^ regulatory T cells, which express high levels of the CCL22 receptor CCR4, also infiltrate tumour sites where they expand in response to TNF and IL-2 produced by effector T cells, and subsequently inhibit the immune response \[[@B17]-[@B19]\].

A lag between the expansion phase of effector T cell and regulatory T cell populations could account for the oscillations in CRP levels observed in cancer patients. If this is the case, oscillations in serum CRP levels could be used to target regulatory T cells for depletion during their expansion phase, by using chemotherapy. Pre-treatment results are reported herein on a prospective phase II trial of cyclophosphamide treatment for gynaecological malignancy, where repeated sampling was taken prior to trial initiation. This allowed the opportunity to assess the hypothesis that CRP levels oscillate, and may be indicative of effector and regulatory T cell proportions and that the latter may also display predictable oscillations in patients with advanced gynaecological malignancies.

Methods
=======

Trial design and patient details
--------------------------------

In total, 19 patients with gynaecological tumours were included in this bicentric phase II trial. The patients had end stage treatment-refractory gynaecological tumours, i.e. ovarian cancer (n = 5), papillary serous cystadenocarcinoma (n = 9), adenocarcinoma (n = 1), serous cystadenocarcinoma (n = 1), endometrial carcinoma (n = 1), peritoneal tumour, (n = 1) or malignant mixed müllerian tumours (n = 1) and were recruited from the Royal Women's Hospital, Melbourne, Australia (n = 12) and the University Hospital Leuven, Belgium (n = 7). Patient age ranged from 43--82 years (Table [1](#T1){ref-type="table"}). The relative institution's research and ethics committees approved the study. From the time of recruitment, written consent was obtained from patients and 7 blood collections were performed over 12 days with daily and second daily bleeds, to assess the presence of a CRP cycle. Blood was collected in the morning on days 1, 3, 5, 6, 8, 10 and 12 with one exception who had blood collected on days 1, 2, 4, 5, 6, 8, 12. Following collection, the blood samples were immediately transported to the laboratory for processing with a maximum of 12 hours between blood collection and freezing of plasma. Based on predicted CRP cycling patterns \[[@B13]\], patients went on to received treatment with low-dose cyclophosphamide, 50 mg administered p.o. twice daily for 3 consecutive days. Blood was also collected from 7 healthy volunteers at the Alfred Hospital, Melbourne, Australia. Ethics was obtained from the institution's research board and written consent was also obtained from the volunteers. The blood collection protocol for the healthy volunteers was similar to that of the cancer patients.

###### 

Patient summary

  **Patient ID**   **Age**   **Tumour type**                           **Prior treatment**                                      **Disease status at inclusion**
  ---------------- --------- ----------------------------------------- -------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  IRS 11           70        Papillary serous cystadenocarcinoma       Surgery, 2 lines chemo,                                  Progessive disease (PD) with rising CA125
  IRS 12           79        Papillary serous cystadenocarcinoma       Surgery, 2 lines chemo,                                  PD -- with progressive nodal abnormalities above and below diaphragm and new peritoneal abdo/pelvic disease
  IRS 13           69        Papillary serous cystadenocarcinoma       Surgery, 2 lines chemo,                                  PD with short bowel syndrome
  BLV 01           74        Ovarian carcinoma                         Surgery, 3 lines chemo                                   PD with newly formed hepatic lesion, hepatogastric, lymph node, peritoneal and mesenteric lesions present
  BLV 02           80        Ovarian carcinoma                         Surgery, 3 lines chemo, provera                          PD with increase of peritoneal metastases with ascites formation
  BLV 03           73        Ovarian carcinoma                         3x surgery, 4 lines chemo                                PD with increase and new formation of abdominal metastases and possible lymph node metastases
  BLV 04           64        Peritoneal tumour                         Surgery, 6 lines chemo, avastin                          PD with peritoneal, omental, vertebral, hepatic and possible gastric metastases
  BLV 05           62        Endometrial carcinoma                     2x surgery, 1 line chemo, radiotherapy                   PD with increase of hepatic, brain and possible renal metastases
  BLV 06           74        Malignant mixed Müllerian tumour (MMMT)   Surgery, 1 line chemo                                    PD with increase of known retroperitoneal lesions and occurrence of a new lesion
  BLV 07           82        Ovarian carcinoma                         2x surgery, 5 lines chemo, provera                       PD with increase of LN metastases in upper abdomen, metastases in mediastinum and formation of lung metastases
  IRS 01           43        Adenocarcinoma                            Surgery, 1 line chemo, radiotherapy and EGFR inhibitor   PD with recurrence in supraclavicular fossa lymph node
  IRS 02           45        Ovarian carcinoma                         Surgery, 3 lines chemo, radiotherapy                     PD with hepatic involvement
  IRS 03           54        Papillary serous cystadenocarcinoma       Surgery, 2 lines chemo, radiotherapy                     PD with rising CA-125 marker
  IRS 04           63        Papillary serous cystadenocarcinoma       Surgery, 5 lines chemo, hormone therapy                  PD with rising CA-125 marker
  IRS 05           68        Serous cystadenocarcinoma                 2x Surgery, 1 line chemo, hormone therapy                PD with rising CA-125 marker
  IRS 06           74        Papillary serous cystadenocarcinoma       Surgery, 2 lines chemo                                   PD rising CA-125 marker, PAN and adrenal gland involvement
  IRS 07           66        Papillary serous cystadenocarcinoma       Surgery, 3 line chemo, radiotherapy, 1x EGFR inhibitor   PD with rising CA125
  IRS 08           63        Papillary serous cystadenocarcinoma       Surgery, 2 lines chemo                                   PD with rising CA125 level
  IRS 09           63        Papillary serous cystadenocarcinoma       Surgery, 5 lines chemo                                   PD with omental mass increased in size

hsCRP plasma level measurements
-------------------------------

Plasma was isolated from whole blood collected either in EDTA-coated tubes (Belgian patients) or in serum separation tubes (Australian patients) by centrifugation. After removing cellular and protein debris, plasma was aliquoted and stored at −80°C for later use. Hs CRP levels were determined by ELISA (Human High Sensitivity C-Reactive Protein ELISA kit; Cusabio Biotech Co., LTD, China) according to manufacturer's instructions. For each treatment cycle, batch analysis was performed on all the necessary samples. To increase experimental precision, all samples were analysed in duplicate.

Peripheral blood mononuclear cells isolation
--------------------------------------------

Mononuclear cells were obtained from peripheral whole blood collected in EDTA-coated tubes via Ficoll (Amersham Pharmacia Biotech, Sweden) density gradient centrifugation. The isolated PBMCs were cryopreserved using a freeze mixture containing 10% DMSO (Sigma-Aldrich, Australia) and either 90% Foetal Calf Serum (Australian samples, JRH Bioscience) or human AB serum (Belgian samples, Sera Laboratories International) and stored in freezing containers (Nalgene) and finally in liquid nitrogen until use. For use, cells were thawed in a 37°C water-bath and quickly re-suspended using AIM-V media (Invitrogen) with 5% human serum (Sigma). PBMC samples were available at all time points from 10 patients in total.

Flow cytometric analysis
------------------------

To determine the frequency and phenotype of T cell populations in PBMCs of patients with gynaecological malignancies and age matched female, healthy volunteers, multicolour flow cytometric analysis was performed using the following surface antibodies: anti-CD3 Q655 (Invitrogen), anti-CD4 AF700 (BD Pharmingen), anti-CD25 PE (BD Pharmingen), and anti-CD127 Biotin (BD Pharmingen). Following primary staining, a fixable dead cell dye (Invitrogen) was also used to distinguish between dead and live cells. Intracellular levels of FoxP3 were determined following fixation and permeabilization using a fixation/permeabilization buffer kit (eBioscience) then staining with anti-FoxP3 PercpCy5.5 (eBioscience). Flow cytometry data was acquired on a Becton Dickinson LSR II using FACSDiva software, collecting a minimum of 100,000 events per sample. Fluorescence minus one (FMO) and isotype matched antibodies were used as controls with all samples. Data were analysed using Flowjo software (TreeStar).

Serum cytokine analysis
-----------------------

To assess serum IL-6 concentration, frozen sera from all patients were thawed over night at 4°C. BD™ Cytometric bead array was used for IL-6 (BD) detection in 50 μl of undiluted serum following the instructions prescribed by the manufacturer. Samples were then acquired by Flow cytometry on a Becton Dickinson LSR II using FACSDiva software, collecting a maximum of 5,000 events per sample. Data were analysed using Flowjo software (TreeStar).

Statistics
----------

To determine the respective periodicity of serum CRP concentration, and Teff and Treg frequencies periodogram analysis was used. The null hypothesis was that there was no consistent period to the measurements, which implies no peaks in the mean periodogram beyond noise. Individual subjects' periodograms were calculated and standardized to have sum of squares equal to 1, then averaged pointwise. Under the null hypothesis, the population pointwise mean periodogram is a horizontal line at 1. The pointwise, lower one-sided 95% confidence bound for the mean periodogram was calculated by the bias-corrected bootstrap method. This lower confidence bound was then compared to the null mark at 1. Exceeding 1 at a peak would be necessary to suggest a significant peak.

The Pearson correlation coefficient between T~eff~ first differences and CRP first differences was estimated for each subject, and the Wilcoxon signed rank test was used to test whether the mean correlation coefficient was non-zero. The same procedure was performed to test for a relationship between T~reg~ and CRP, T~regs~ and T~effs~, and CRP and IL-6. The first difference is defined as the change in value from one time point to the next.

Coefficients of variation in the frequencies of T~regs~ and T~effs~ among 7 time points over a period of 12 days were determined by initially calculating the standard deviation, which was then expressed as percentages of the mean frequency of the respective population over the 7 time points. Statistical significances between mean values of T~reg~ and T~eff~ frequencies as well as coefficients of variation for both populations were calculated using non-parametric (Wilcoxon Mann Whitney) tests. P values \< 0.05 were considered significant. All mean values were presented ± the standard error from the mean (SEM).

Results
=======

CRP levels, and T~reg~ and T~eff~ frequencies did not appear to be oscillatory
------------------------------------------------------------------------------

The oscillation in serum CRP concentration with a period of 7 days has previously been reported in 15 late-stage advanced melanoma and 4 late-stage advanced ovarian cancer patients \[[@B13]\]. In a cohort of 19 patients with gynaecological malignancies, we investigated the periodicity of serum CRP concentration oscillations over time (raw data provided in Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). In the individual patients, serum CRP concentrations appeared to fluctuate over time (Figure [1](#F1){ref-type="fig"}A), however when a mean standard periodogram analysis was carried out for the pooled patient cohort at every time point, while small peaks were apparent in the periodograms at 3.6 days and 4.6 days, neither was significant (Figure [1](#F1){ref-type="fig"}A). In a smaller cohort of 10 patients from whom PBMCs were collected, the periodicity of peripheral blood T~reg~ and T~eff~ frequencies was also investigated. T~regs~ were defined as expressing high levels of CD25 and FoxP3, which we confirmed expressed low levels of CD127, while T~effs~ were defined as expressing intermediate levels of CD25 (Additional file [2](#S2){ref-type="supplementary-material"}: Figure S1) as per previous studies \[[@B20],[@B21]\]. Similar to serum CRP concentration, both frequencies appeared to fluctuate over time, in some individual patients (Figure [1](#F1){ref-type="fig"}B and C). In the pooled cohort, mean standard periodogram analysis revealed small peaks for T~reg~ frequencies at 4.8 days and for T~eff~ frequencies at 3.6 and 4.6 days, but none was significant (Figure [1](#F1){ref-type="fig"}B and C) statistically at the p = 0.05 level.

![**The periodicity of serum CRP concentration, and T**~**reg**~**and T**~**eff**~**frequency.** Patients with gynaecological malignancies had blood collected 7 times over a period of 12 days. Serum was collected from 19 patients. While in 10 of the patients, PBMCs were also isolated. CRP levels in sera were determined along with the frequencies of Tregs and Teff within CD4^+^ T cells from PBMCs. The values for **A**, serum CRP concentration (n = 19, solid lines use the left Y axis while dashed lines use the right Y axis) (mg/L), **B** Treg and **C**, Teff frequencies (%, n = 10, solid lines use the left Y axis while dashed lines use the right Y axis) over time (days) were plotted in spaghetti plots. The periodicity for **A**, CRP concentration, **B**, Treg and **C**, Teff frequencies were assessed using the null hypothesis, that the population pointwise mean periodogram was a horizontal line at 1 (dotted line). The pointwise lower one-sided 95% confidence bound (dashed line) needed to exceed the null mark (dotted line) to suggest a significant peak.](1479-5876-12-179-1){#F1}

Serum CRP concentrations were not correlated with T~reg~ or T~eff~ frequencies
------------------------------------------------------------------------------

Although there was no evidence of a predictable oscillatory pattern of serum CRP concentration over time, we investigated whether CRP could still be used as a surrogate marker for T~reg~ or T~eff~ frequency in peripheral blood. Using the 10 patients from which, both serum and PBMCs were collected, serum CRP concentrations from each time point within each individual patient were then correlated with serum IL-6 concentration as well as the corresponding frequencies of T~regs~ or T~effs~. The correlation coefficients from the patients showed a significant positive correlation between serum CRP and serum IL-6 concentrations (p = 0.03; Table [2](#T2){ref-type="table"}). However, there appeared to be no apparent relationship between serum CRP concentration, and T~reg~ or T~eff~ frequencies (Table [3](#T3){ref-type="table"} and Table [4](#T4){ref-type="table"}). T~regs~ and T~effs~ frequencies on the other hand, correlated significantly with each other (p = 0.01; Table [5](#T5){ref-type="table"}).

###### 

Correlation coefficients of CRP vs IL-6

  **Stem**   **Leaf**
  ---------- ----------
  −0         32210
  0          11113344
  0          5579

null hypothesis: correlation coefficient mean = 0.

V = 98.5 p = 0.03 (Wilcoxon signed rank test).

###### 

Correlation coefficients of CRP vs Tregs

  **Stem**   **Leaf**
  ---------- ----------
  −0         320
  0          124
  0          5788

null hypothesis: correlation coefficient mean = 0.

V = 45 p = 0.08 (Wilcoxon signed rank test).

###### 

Correlation coefficients of CRP vs Teffs

  **Stem**   **Leaf**
  ---------- ----------
  −0         6
  −0         100
  0          122
  0          679

null hypothesis: correlation coefficient mean = 0.

V = 42 p = 0.16 (Wilcoxon signed rank test).

###### 

Correlation coefficients of Tregs vs Teffs

  **Stem**   **Leaf**
  ---------- ----------
  −0         32
  0          44
  0          56889
  1          0

null hypothesis: correlation coefficient mean = 0.

V = 52 p = 0.01 (Wilcoxon signed rank test).

Disease state in the cancer patients did not increase the variation of T~reg~ or T~eff~ frequencies within CD4^+^ T cells over time
-----------------------------------------------------------------------------------------------------------------------------------

There did not appear to be a correlative linear relationship between inflammation as shown by serum CRP concentration and peripheral blood T~regs~ and T~effs~ frequencies. We investigated whether the disease state in patients may still influence the magnitude of variation in the frequencies of T~regs~ and T~effs~ over time. We initially compared the mean frequencies of T~regs~ and T~effs~ within CD4+ T cells between 10 cancer patients and 7, age and sex matched, healthy donors. Although the mean frequency of T~effs~ only, was significantly lower in cancer patients (8% ± 2%) than healthy donors (11% ± 0.6%, p = 0.005; Figure [2](#F2){ref-type="fig"}A), the mean ratio of T~effs~ to T~regs~ was not significantly different. We then assessed whether cancer patients, who have raised inflammation, evident by higher CRP levels relative to healthy individuals \[[@B13]\], exhibited greater variation in the frequencies of either T~regs~ or T~effs~ over time. The variation in T~reg~ and T~eff~ frequencies from 7 blood collections over a 12-day period was compared between the 7 healthy volunteers and 10 cancer patients. Both cancer patients and healthy volunteers had a similar mean coefficient of variation in T~reg~ frequency (26% ± 5% and 29% ± 3% respectively, Figure [2](#F2){ref-type="fig"}B). The mean coefficient of variation in T~effs~ frequency was significantly lower in cancer patients (13% ± 1%, p = 0.002) compared to healthy volunteers (22% ± 2%, Figure [2](#F2){ref-type="fig"}B). While the mean coefficient of variation in the ratio of T~effs~ to T~regs~ was lower in cancer patients compared to healthy volunteers (21.7% ± 3.3% and 27.8% ± 2.2%, Figure [2](#F2){ref-type="fig"}B), this was not significant.

![**Variation in T**~**reg**~**and T**~**eff**~**frequencies. A**, The mean frequency from 7 readings of T~regs~ and T~effs~ over a period of 12 days was obtained for each of 10 cancer patients and 7 healthy donors. The ratio of T~eff~ to T~regs~ was also calculated. **B**, The coefficients of variation in the frequencies of T~regs~ and T~effs~ as well as the ratio of T~effs~ to T~regs~ were determined by calculating the standard deviation among the 7 time points for each cancer patient and healthy donor and expressing it as a percentage of the mean frequency. Wilcoxon and Mann Whitney tests were used to determine significant differences between mean values, with p \< 0.05 indicating significance. Graphs show mean ± standard error from the mean (SEM).](1479-5876-12-179-2){#F2}

Discussion
==========

The dynamic nature of the adaptive immune responses has been described in two ways. Firstly, there are diurnal fluctuations, regulated by the circadian clock exemplified in CD4 T cells by the rhythmic expression of genes that control cytokine secretion and cell function \[[@B22]\]. Secondly, antigen dependent fluctuations occur during acute infections and the kinetics of the immune response are controlled by a system of positive and negative feedback mechanisms designed to limit the immune response when pathogenic insults are resolved. In chronic diseases such as cancer, antigenic clearance does not occur and the persistent antigen exposure results in a constant state of immune activation. The tumour however, limits immune activation by secreting immune inhibitory cytokines such as IL-10, and tumour growth factor (TGF)-β as well as inducing regulatory cell populations including myeloid derived suppressor cells (MDSCs) and regulatory T cells \[[@B18],[@B23]-[@B25]\]. Although intratumoural immune cells are skewed towards immune inhibition, there may still exist a homeostatic balance that needs to be maintained in the periphery of cancer patients in which an oscillating sequence of immune activation is followed by negative feedback immune suppression \[[@B13]\]. The study herein however, showed that CRP concentrations in all the patients did not appear to oscillate periodically nor did the concentration of CRP correlate significantly with T~reg~ or T~eff~ frequencies. Therefore, CRP may not be a practical useful surrogate marker for either cell population. In a study of 12 patients with melanoma, less than 50% showed possible time dependent CRP concentration profiles \[[@B26]\]. The two data sets available therefore suggest that inflammation in cancer patients may not consistently follow an oscillatory, sinusoidal (or other mathematical) pattern with a constant period or amplitude. This may be because any such model oversimplifies the inflammatory process, and correlations are easily disrupted by a number of potential additional *in vivo* co-parameters or process variations. Multiple factors influence the levels of cytokines that regulate inflammation. One such factor is the tumour growth. In patients with papillary thyroid cancer CD4^+^ T cell frequencies correlate with tumour size while T~reg~ frequencies correlate with lymph node metastasis \[[@B27]\]. Such variables may hence significantly influence the magnitude of T cell effector and suppressor frequency and function.

In our study, neither the coefficient of variation of both T~regs~ and T~effs~ nor that of the ratio of T~eff~ to T~regs~, in cancer patients was greater than that of healthy donors suggesting that in the periphery the fluctuation of T~reg~ within the CD4 population was not affected by the presence of the tumour. The coefficient of variation of T~effs~ was lower in cancer patients compared to healthy donors, which may have been due to immune suppression. Consistent with this suggestion, the frequency of T~effs~ was significantly lower in the patients than in healthy donors. Although T~reg~ frequencies in the periphery were not significantly increased, other cell subsets such as MDSCs may also facilitate immune suppression. Pro-inflammatory mediators have also been suggested to promote accumulation of MDSC in cancer patients' peripheral blood \[[@B28]\]. Within the tumour microenvironment, the fluxes between T~reg~ and T~eff~ populations may be more evident.

Although changes in the frequencies of conventional T~reg~ and T~eff~ did not correlate with inflammation, it is still possible that minor subsets within each phenotype (T~reg~ or T~eff~) or their specific function over time, may correlate. Indeed, effector and regulatory T cells are heterogeneous populations of cells. Further breaking down these populations based on phenotype and function may also show greater variation between patients and healthy donors. For example, T~reg~ populations with enhanced suppressive function due to elevated expression of inhibitory receptors such as glucocorticoid induced tumour necrosis factor receptor (GITR) and cytotoxic T-lymphocyte antigen (CTLA)-4 as well as increased production of suppressive factors such as adenosine and cytokines TGF-β and IL-10, have been reported to be elevated in cancer patients \[[@B29]-[@B31]\]. Similarly, effector T cells can be broken down into different functional phenotypes such as IL-17 secreting and type-1 interferon secreting T~effs~. Type-1 interferon secreting T~effs~ promote proliferation of cytotoxic CD8 T cells, which contribute towards an anti-tumour effect \[[@B32]-[@B35]\]. It cannot therefore be excluded that the frequencies of some of these functional subsets, as well as CD8 T cells, may be subject to regulation by inflammatory factors, even when the results presented herein show that total T~reg~ and T~eff~ populations are not correlated to inflammatory status as reflected by CRP levels in blood. Mathematical models that aim to predict the balance that exists between immune activation and regulation within accessible blood samples, will therefore benefit from additionally taking into account the following variables: i) the effect of diurnal variation ii) the tumour growth rate iii) the heterogeneity present within both regulatory and effector T cell populations.

In conclusion, in our sample of patients with gynaecological malignancies, CRP concentrations do not oscillate in a consistent predictable manner, and do not correlate either positively or negatively with conventional T~reg~ or T~eff~ subsets. Therefore, there is no evidence to suggest that CRP can reliably be used across cancer patients as a surrogate, time-sensitive and most importantly, predictive marker, to reflect circulating effector or regulatory T cell frequencies, as previously suggested \[[@B13]\]. Time based therapy founded on modelling a consistent cyclical pattern of inflammation using serum CRP concentration as a predictive marker of regulatory T cell expansion may not be possible. However, we cannot exclude that further investigating the kinetics of inflammation in cancer patients, perhaps by taking more frequent blood samples or else by taking into consideration multiple inflammatory and immune-regulatory parameters, the progressive nature of immune suppression, as well as the heterogeneity of effector and regulatory T cell populations could all help in modelling more complex, and potentially predictive, equations.
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=============

T~regs~: Regulatory T cells; T~effs~: Effector T cells; CRP: C reactive protein.
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###### Additional file 1: Table S1a

CRP raw data**. Table S1b.** Treg and Teff frequency raw data.
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###### Additional file 2: Figure S1

Gating strategy for T~regs~ and T~effs~. Peripheral blood mononuclear cells were stained for the following markers CD3, CD4, CD25 and FoxP3. A, T~effs~ (dashed line) were defined as CD3^+^CD4^+^CD25^intermediate^ while T~regs~ (dotted line) were CD3^+^CD25^Hi^FoxP3^+^. B, FoxP3 and CD127 expression on Tregs (solid line) and Teffs (dashed line).
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